Clinical Trial Update: A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and immune response of the AS37 adjuvant combined with Hepatitis B antigen in adults 18-45; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• AS37 (AS37)
• Hepatitis B antigen (Hepatitis B antigen)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 1 | Status: COMPLETED | Results posted: 2026-01-15